Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9PIK3CAPIK3CBPIK3CD
The experimentally established mechanism targets of Fimepinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 19/20 | 0.99 |
| ▸ | HDAC2 known ✓ | Q92769 | 7/20 | 0.99 |
| ▸ | HDAC10 known ✓ | Q969S8 | 7/20 | 0.99 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 7/20 | 0.99 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 6/20 | 0.99 |
| ▸ | HDAC3 known ✓ | O15379 | 6/20 | 0.99 |
| ▸ | HDAC4 known ✓ | P56524 | 5/20 | 0.99 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 5/20 | 0.99 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 5/20 | 0.99 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 5/20 | 0.99 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 5/20 | 0.99 |
| ▸ | PIK3CA known ✓ | P42336 | 4/20 | 0.99 |
| ▸ | PIK3CD known ✓ | O00329 | 3/20 | 0.99 |
| ▸ | PIK3CB known ✓ | P42338 | 2/20 | 0.99 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.99 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.99 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.99 |
| ▸ | MTOR | P42345 | 2/20 | 0.99 |
| ▸ | PRKDC | P78527 | 1/20 | 0.99 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fimepinostat SCHEMBL12813122 | 1.00 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL1284705 | 0.99 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29353052 | 0.99 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29493089 | 0.99 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813120 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666301 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813054 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813051 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813474 | 0.96 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813327 | 0.96 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3849554-B1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220249502-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220168284-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249502-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | PDPK1, PDCD1, PDCD1LG2 | HDAC1 19/4885HDAC2 61/4885HDAC10 69/4885 |
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | PDPK1, PDCD1, PDCD1LG2 | HDAC1 19/4885HDAC2 61/4885HDAC10 69/4885 |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | HDAC1, PI4KA, PDPK1 | HDAC1 1/4885HDAC2 22/4885HDAC10 27/4885 |
| US-20220168284-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | HDAC1, PI4KA, PDPK1 | HDAC1 1/4885HDAC2 22/4885HDAC10 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.